您好，欢迎来到半岛电竞官方网址 ！ [ 登录] [ 免费注册]
半岛电竞官方网址
发布求购
位置： 首页> 半岛bd体育手机客户端 库> PI3K/mTOR Inhibitor-1
立即咨询
咨询类型：
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
PI3K/mTOR Inhibitor-1
本半岛bd体育手机客户端 不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
PI3K/mTOR Inhibitor-1图片
CAS NO: 1949802-49-6
包装与价格：
包装 价格(元)
100mg 电议
250mg 电议
500mg 电议

半岛bd体育手机客户端 介绍
PI3K/mTOR Inhibitor-1 是一种有效的，口服生物可利用的双重 PI3K/ mTOR抑制剂，抑制 PI3Kα/ PI3Kβ/ PI3Kγ/ PI3Kδ和 mTOR， IC50分别为 20/376/204/46 nM 和 186 nM。具有抗肿瘤活性。
生物活性

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dualPI3K/mTORinhibitor withIC50s of 20/376/204/46 nM and 186 nM forPI3Kα/PI3Kβ/PI3Kγ/PI3KδandmTOR, respectively[1]. Antitumor activity[1].
IC50& Target[1]

PI3Kα

20 nM (IC50)

PI3Kβ

376 nM (IC50)

PI3Kγ

204 nM (IC50)

PI3Kδ

46 nM (IC50)

mTOR

186 nM (IC50)
体外研究
(In Vitro)

PI3K/mTOR Inhibitor-1 (Compound 26) also exhibits potent functional suppression of AKT phosphorylation (IC50=196 nM)[1].
PI3K/mTOR Inhibitor-1 (0.046-10 μM, 72 hours) exhibits excellent antiproliferative effects on a panel of cancer cells. PI3K/mTOR Inhibitor inhibits A431, A549, PC3, MDA-MB-361, SW480, ES-2, HT29, SK-OV-3, HCT116 , G401 , BT20 ,DLD1 HCC827, H1650, H460, Farage, H820, HCT15, H358, Colo-205, PC9, H1975, WSU-DLCL2, HT, A2780, SU-DHL-10, Toledo,SU-DHL-6, DB, and Pfeiffer cells with IC50s of 0.188, 0.104, 0.063, 0.085, 0.534, 0.179, 0.163, 0.135, 0.308, 0.113, 0.729, 0.264, 0.287, 1.662, 0.611, 0.202, 0.365, 0.104, 0.098, 0.109, 0.237, 0.136, 0.145, 0.090, 0.251 0.215, 0.269, 0.111 0.062, and 0.061 μM, respectively[1].

Cell Proliferation Assay[1]

Cell Line: U87-MG, A431, MCF-7, PC3, A549, MDA-MB-361, SW480, ES-2, HT29, SK-OV-3, HCT116, G401, BT20, DLD1, HCC827, H1650, H460, Farage, H820, HCT15, H358, Colo-205, PC9, H1975, WSU-DLCL2, HT, A2780, SU-DHL-10, Toledo, SU-DHL-6, DB, Pfeiffer cells
Concentration: 0.046-10 μM
Incubation Time: 72 hours
Result: Inhibited HT-29 cells proliferation with an IC50of 0.163 μM.
体内研究
(In Vivo)

PI3K/mTOR Inhibitor-1 (Compound 26) produces 54.4% tumor growth inhibition (TGI) with daily oral doses of 3.75 mg/kg for 27 days. The 7.5 mg/kg group of PI3K/mTOR Inhibitor-1 displays more significant TGI (72.9%). All animals survive after 27-day treatment, whereas 15% weigh loss is observed in PI3K/mTOR Inhibitor-1, 7.5 mg/kg group[1].

Animal Model: Balb/cnu/numice with HT-29 colorectal carcinoma xenograft mouse model carrying thePIK3CAP449T mutation[1]
Dosage: 3.75 and 7.5 mg/kg
Administration: Oral gavage daily for 27 days
Result: Tumor growth inhibition (TGI) was 54.4% and 72.9% for daily oral doses of 3.75 mg/kg and 7.5 mg/kg for 27 days, respectively.
分子量

407.46
Formula

C18H22FN5O3S
CAS 号

1949802-49-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Baidu
map